Collegium Pharmaceutical, Inc. (COLL)
USD 26.73
(1.63%)
USD 26.73
(1.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 166.96 Million USD | 259.66% |
| 2022 | -104.57 Million USD | -123.93% |
| 2021 | -46.69 Million USD | -818.19% |
| 2020 | -5.08 Million USD | 78.58% |
| 2019 | -23.74 Million USD | -14.81% |
| 2018 | -20.68 Million USD | 72.58% |
| 2017 | -75.44 Million USD | 19.81% |
| 2016 | -94.08 Million USD | -249.66% |
| 2015 | -26.9 Million USD | -52.32% |
| 2014 | -17.66 Million USD | -10.12% |
| 2013 | -16.04 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 47.47 Million USD | -4.05% |
| 2024 Q1 | 49.47 Million USD | -19.8% |
| 2023 Q1 | 24.62 Million USD | 181.22% |
| 2023 Q3 | 45.01 Million USD | 26.32% |
| 2023 Q2 | 35.63 Million USD | 44.69% |
| 2023 FY | 166.96 Million USD | 259.66% |
| 2023 Q4 | 61.68 Million USD | 37.04% |
| 2022 Q3 | 20.46 Million USD | 84.22% |
| 2022 FY | -104.57 Million USD | -123.93% |
| 2022 Q1 | -10.01 Million USD | 70.66% |
| 2022 Q4 | -30.32 Million USD | -248.14% |
| 2022 Q2 | 11.11 Million USD | 210.98% |
| 2021 FY | -46.69 Million USD | -818.19% |
| 2021 Q4 | -34.12 Million USD | -341.16% |
| 2021 Q1 | 21.19 Million USD | 41.32% |
| 2021 Q2 | 16.4 Million USD | -22.57% |
| 2021 Q3 | 14.14 Million USD | -13.77% |
| 2020 Q4 | 14.99 Million USD | -23.59% |
| 2020 Q3 | 19.62 Million USD | 18.59% |
| 2020 Q2 | 16.54 Million USD | 226.99% |
| 2020 FY | -5.08 Million USD | 78.58% |
| 2020 Q1 | 5.06 Million USD | 313.27% |
| 2019 Q4 | -2.37 Million USD | 62.78% |
| 2019 Q3 | -6.37 Million USD | -27.3% |
| 2019 Q2 | -5 Million USD | 49.88% |
| 2019 FY | -23.74 Million USD | -14.81% |
| 2019 Q1 | -9.99 Million USD | -190.83% |
| 2018 Q2 | -7.29 Million USD | 44.78% |
| 2018 Q1 | -13.2 Million USD | 24.89% |
| 2018 Q4 | 11 Million USD | 198.35% |
| 2018 FY | -20.68 Million USD | 72.58% |
| 2018 Q3 | -11.18 Million USD | -53.38% |
| 2017 Q4 | -17.58 Million USD | -30.92% |
| 2017 Q3 | -13.43 Million USD | 36.82% |
| 2017 Q1 | -23.17 Million USD | 15.97% |
| 2017 FY | -75.44 Million USD | 19.81% |
| 2017 Q2 | -21.25 Million USD | 8.28% |
| 2016 Q4 | -27.57 Million USD | -4.3% |
| 2016 FY | -94.08 Million USD | -249.66% |
| 2016 Q3 | -26.44 Million USD | -8.04% |
| 2016 Q2 | -24.47 Million USD | -57.02% |
| 2016 Q1 | -15.58 Million USD | -65.19% |
| 2015 FY | -26.9 Million USD | -52.32% |
| 2015 Q3 | -9.26 Million USD | -102.51% |
| 2015 Q2 | -4.57 Million USD | -26.03% |
| 2015 Q1 | -3.63 Million USD | -9.11% |
| 2015 Q4 | -9.43 Million USD | -1.85% |
| 2014 Q4 | -3.32 Million USD | 48.85% |
| 2014 FY | -17.66 Million USD | -10.12% |
| 2014 Q3 | -6.5 Million USD | -59.12% |
| 2014 Q1 | -3.74 Million USD | 0.0% |
| 2014 Q2 | -4.08 Million USD | -9.19% |
| 2013 FY | -16.04 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Embecta Corp. | 221.5 Million USD | 24.623% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | -255.455% |
| Dynavax Technologies Corporation | -37.02 Million USD | 550.905% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 207.327% |
| Pacira BioSciences, Inc. | 87.67 Million USD | -90.432% |
| PainReform Ltd. | -9.58 Million USD | 1842.081% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 1205.556% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 3589.04% |
| SCYNEXIS, Inc. | 72.66 Million USD | -129.755% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 6738.036% |
| Cosmos Health Inc. | -21.83 Million USD | 864.781% |
| Journey Medical Corporation | -2.07 Million USD | 8154.076% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 3589.04% |
| Safety Shot Inc | -12.18 Million USD | 1470.313% |
| Alpha Teknova, Inc. | -35.56 Million USD | 569.48% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 204.756% |
| Bright Green Corporation | -8.89 Million USD | 1977.785% |
| Procaps Group, S.A. | 38.97 Million USD | -328.402% |
| Theratechnologies Inc. | -10.62 Million USD | 1671.102% |
| Harrow Health, Inc. | 580 Thousand USD | -28686.379% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 3651.606% |
| Biofrontera Inc. | -22.67 Million USD | 836.257% |
| DURECT Corporation | -36.88 Million USD | 552.665% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 3268.742% |
| Cronos Group Inc. | -81.37 Million USD | 305.174% |
| OptiNose, Inc. | -22.74 Million USD | 833.959% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 20.128% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 526.432% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -1221.731% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -1233.022% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 3950.295% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 2788.228% |
| Radius Health, Inc. | -3.92 Million USD | 4353.783% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 4834.1% |
| ProPhase Labs, Inc. | -21.61 Million USD | 872.503% |
| Phibro Animal Health Corporation | 53.31 Million USD | -213.16% |
| Procaps Group S.A. | 52.32 Million USD | -219.091% |
| Alvotech | -354.86 Million USD | 147.05% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 2058.946% |
| Viatris Inc. | 766.2 Million USD | 78.209% |
| Rockwell Medical, Inc. | -6.67 Million USD | 2603.163% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 3277.788% |
| SIGA Technologies, Inc. | 83.62 Million USD | -99.664% |
| Tilray Brands, Inc. | -174.74 Million USD | 195.546% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -1689.315% |
| Shineco, Inc. | -17.06 Million USD | 1078.333% |
| PetIQ, Inc. | 60.01 Million USD | -178.199% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 3624.819% |
| Incannex Healthcare Limited | -30.04 Million USD | 655.777% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 33.455% |
| Alimera Sciences, Inc. | -1.47 Million USD | 11450.17% |
| Silver Spike Investment Corp. | 7.34 Million USD | -2174.639% |
| Assertio Holdings, Inc. | -243.53 Million USD | 168.557% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 2933.507% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 1326.089% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 1170.675% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 932.721% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 221.119% |
| Hempacco Co., Inc. | -8.81 Million USD | 1994.64% |
| Talphera, Inc. | -16.88 Million USD | 1088.578% |
| Alvotech | -354.86 Million USD | 147.05% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | -212.345% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 54.212% |
| Currenc Group, Inc. | -6.64 Million USD | 2612.284% |
| Kamada Ltd. | 10.06 Million USD | -1558.992% |
| Indivior PLC | -4 Million USD | 4274.025% |
| Evoke Pharma, Inc. | -7.43 Million USD | 2346.85% |
| Flora Growth Corp. | -50.35 Million USD | 431.574% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 932.721% |
| Evolus, Inc. | -49.23 Million USD | 439.124% |
| HUTCHMED (China) Limited | 18.37 Million USD | -808.631% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 15.243% |
| Akanda Corp. | -10.05 Million USD | 1761.077% |